- Home
- EQ vs PMEC Comparison
EQ vs PMEC Comparison
Compare EQ & PMEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- PMEC
- Stock Information
- Founded
- EQ 2017
- PMEC 1984
- Country
- EQ United States
- PMEC Singapore
- Employees
- EQ N/A
- PMEC N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- PMEC
- Sector
- EQ Health Care
- PMEC
- Exchange
- EQ Nasdaq
- PMEC Nasdaq
- Market Cap
- EQ 24.8M
- PMEC 29.3M
- IPO Year
- EQ 2018
- PMEC 2023
- Fundamental
- Price
- EQ $0.74
- PMEC $0.75
- Analyst Decision
- EQ Buy
- PMEC
- Analyst Count
- EQ 2
- PMEC 0
- Target Price
- EQ $5.00
- PMEC N/A
- AVG Volume (30 Days)
- EQ 304.3K
- PMEC 76.4K
- Earning Date
- EQ 11-13-2024
- PMEC 12-26-2024
- Dividend Yield
- EQ N/A
- PMEC N/A
- EPS Growth
- EQ N/A
- PMEC N/A
- EPS
- EQ N/A
- PMEC N/A
- Revenue
- EQ $45,914,000.00
- PMEC $72,524,000.00
- Revenue This Year
- EQ N/A
- PMEC N/A
- Revenue Next Year
- EQ N/A
- PMEC N/A
- P/E Ratio
- EQ N/A
- PMEC N/A
- Revenue Growth
- EQ 7.70
- PMEC 5.07
- 52 Week Low
- EQ $0.48
- PMEC $0.49
- 52 Week High
- EQ $3.25
- PMEC $4.15
- Technical
- Relative Strength Index (RSI)
- EQ 40.86
- PMEC 46.59
- Support Level
- EQ $0.66
- PMEC $0.65
- Resistance Level
- EQ $0.77
- PMEC $0.90
- Average True Range (ATR)
- EQ 0.08
- PMEC 0.09
- MACD
- EQ -0.01
- PMEC -0.00
- Stochastic Oscillator
- EQ 26.09
- PMEC 20.00
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
About PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.